Clinical Trial Update: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update assessing Lepodisiran for reducing major adverse cardiovascular events in adults with elevated lipoprotein(a) and atheroscleroti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Lipoprotein Elevation

Drugs mentioned

• Lepodisiran (LY3819469)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | Phase 3 | Status: ACTIVE_NOT_RECRUITING